Testing a new drug for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called JSKN003 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if this drug can shrink tumors or slow cancer growth. If you qualify, you may receive this experimental treatment and be closely monitored by a study team.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum chemotherapy.
- You are 18 years or older.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are in reasonably good health (able to do daily activities with little or no help).
- You have not had a previous treatment with a type of targeted drug called a topoisomerase I inhibitor antibody-drug conjugate (for example, Enhertu or Trodelvy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new drug called IBI354 against standard chemotherapy for people with ovarian, primary peritoneal, or fallopian tube cancer that stopped responding to platinum-based treatments. It aims to see if the new drug works better and has fewer side effects.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.